RecruitingNot ApplicableNCT06194955
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
The Effect of Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1) and Glucagon-like Peptide-2 (GLP-2) in Individuals With Genetically Altered Receptor Function
Sponsor
University of Copenhagen
Enrollment
60 participants
Start Date
Jan 4, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This project will characterize the physiological effect of the hormones, GIP-, GLP-1- and GLP-2 infusions in a group of individuals that are carriers of GIP-, GLP-1- and GLP-2 receptor gene variants, respectively.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria1
- BMI 19-35 kg/m2
Exclusion Criteria8
- Treatment with medication or supplements that can not be discontinued for 12 hours
- >10 objects of alcohol weekly or abuse of narcotics
- Liver disease (defined as ALAT and/or ASAT ≥ 2 x normal levels)
- Decreased kidney function (creatine levels over reference interval)
- Uncontrollable increased blood pressure (> 140/90 mmHg)
- Low blood percentage (hemoglobin < 8.3 mmol/l)
- Special diet or planned weight change during trial period
- Other conditions that could be expected to affect the primary or secondary outcomes
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGGIP(1-42)
Infusion
DRUGGLP-1
Infusion
DRUGGLP-2
Infusion
OTHERPlacebo
Saline
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06194955